期刊
JOURNAL OF THORACIC ONCOLOGY
卷 13, 期 10, 页码 1519-1529出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2018.06.025
关键词
Lung adenocarcinoma; NSCLC; Biomarkers; Proteomics; Proteogenomics
资金
- Vanderbilt lung cancer NCI SPORE grant [CA090949]
- National Library of Medicine Fellowship [4T15LM011270]
Introduction: Despite apparently complete surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who benefits from adjuvant therapy, the drivers of relapse, and novel targets in this setting. Methods: RNA sequencing and liquid chromatography/liquid chromatography-mass spectrometry proteomics data were generated from 51 surgically resected non-small cell lung tumors with known recurrence status. Results: We present a rationale and framework for the incorporation of high-content RNA and protein measurements into integrative biomarkers and show the potential of this approach for predicting risk of recurrence in a group of lung adenocarcinomas. In addition, we characterize the relationship between mRNA and protein measurements in lung adenocarcinoma and show that it is outcome specific. Conclusions: Our results suggest that mRNA and protein data possess independent biological and clinical importance, which can be leveraged to create higher-powered expression biomarkers. (C) 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据